According to CNN article published April 7th, 2022 “Medicare will restrict coverage of the controversial and costly Alzheimer’s drug Aduhelm to those enrolled in qualifying clinical trials, the Centers for Medicare and Medicaid Services.”
To read the full article click here.
Fox News writes “The first drug proven to slow Alzheimer’s is on sale, but most U.S. patients will not be able to receive the treatment for several…
Researchers from West Virginia University’s Rockefeller Neuroscience Institute have demonstrated in a proof-of-concept study, published in the New England Journal of Medicine, that focused ultrasound…
A new Alzheimer’s drug, Donanemab shows a 35% slowdown in cognitive decline.
Shortly after the FDA approved the much-anticipated Alzheimer’s drug Leqembi as an intravenous infusion, Eisai announced positive results from a study examining a subcutaneous formulation…
Everyone knows that exercise is beneficial to good health and there has been a great deal of research on how it may affect dementia. This…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
Responses